A phase where verification standards determine speed of market entry

In the bio and digital health industries, it is becoming increasingly difficult for products to be recognized for their value based on technological novelty alone, making it a core competitive advantage to determine from the early stages of development what data to prepare and in what order. Korea’s Ministry of Food and Drug Safety has established detailed criteria in digital medical device approvals to distinguish cases where clinical trials are essential from those where performance verification data may be sufficient, while also clarifying the pre-review process for clinical trial plans, making preparation strategies more predictable for developers.

This change is less about easing regulation and more about reducing uncertainty and lowering the cost of trial and error. In fact, as seen in the case where interpretation of participant numbers in an oral insulin clinical trial disclosure caused confusion, the explanatory framework directly affects investment decisions, which is also why global pharmaceutical companies are applying AI to clinical design and document preparation stages to reduce time and costs.

Why quality control has become as important as research outcomes

There is a growing trend that the closer a product is to commercialization, the more it must prove consistency in quality and reliability in use before efficacy. GC Biopharma has secured an analytical system capable of closely tracking stability changes in mRNA lipid nanoparticle (LNP) vaccines, while Sky Labs is accumulating performance evidence for CART BP Pro as it prepares for U.S. approval trials. Meanwhile, a Korea Consumer Agency investigation found that all 30 plant-based melatonin-containing food products contained compounds structurally identical to pharmaceutical ingredients, exposing gaps in the oversight of ordinary food products.

This trend arises because as technologies become more advanced, even small variations in manufacturing, storage, and distribution can undermine trust in a product. As even post-commercialization quality maintenance, such as medicine delivery management during heat waves, becomes part of the evaluation, companies are being burdened with managing not only research and development but the entire supply process.

Platform competition shifts toward securing data and materials

Collaboration among companies, hospitals, and public institutions is expanding beyond individual product development into the building of platforms that accumulate data and raw materials over the long term. DT&CRO and Korea University Guro Hospital are building a precision medicine foundation combining patient-derived organoids (PDOs) and AI, while in the cosmetics and bio-materials sectors, efforts are continuing to scientifically standardize regional resources such as Jeju natural mugwort and the National Institute of Biological Resources in the Honam region and convert them into differentiated materials.

This movement is not simply about finding more new materials, but about the need to connect everything from raw material discovery to efficacy verification, process optimization, and commercialization into a single system in order to remain competitive in global markets over the long term. Ultimately, Korea’s bio industry is shifting toward being evaluated not by a single hit product, but by its ability to secure reproducible data and standardized resources.

Trust risks grow alongside growth expectations

As expectations for market expansion rise, institutions are also responding more sensitively to the possibility of damage to trust. A case in which post-market clinical trials for medical devices were distorted into a means of boosting sales, leading to prosecution over payments totaling 4.2 billion won under the name of research funding, shows that when the boundary between clinical research and marketing becomes blurred, trust in the entire industry is damaged as well.

Accordingly, recent institutional changes are moving in two directions at once: encouraging innovation while also tightening quality and ethical standards. The policy to phase in GMP for veterinary drugs from 2030 to 2035 reflects the same context, implying that Korea’s bio industry will need not only fast development but also verifiable operational systems in order to gain credibility in both exports and investment going forward.